98 related articles for article (PubMed ID: 23324501)
1. Effect of concurrent prescription antiarthralgia pharmacotherapy on persistence to aromatase inhibitors in treatment-naive postmenopausal females.
Hashem MG; Cleary K; Fishman D; Nichols L; Khalid M
Ann Pharmacother; 2013 Jan; 47(1):29-34. PubMed ID: 23324501
[TBL] [Abstract][Full Text] [Related]
2. A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients' persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer.
Yu KD; Zhou Y; Liu GY; Li B; He PQ; Zhang HW; Lou LH; Wang XJ; Wang S; Tang JH; Liu YH; Wang X; Jiang ZF; Ma LW; Gu L; Cao MZ; Zhang QY; Wang SM; Su FX; Zheng H; Li HY; Tang LL; Sun SR; Liu JP; Shao ZM; Shen ZZ
Breast Cancer Res Treat; 2012 Jul; 134(1):307-13. PubMed ID: 22527106
[TBL] [Abstract][Full Text] [Related]
3. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance.
Hertz RP; Unger AN; Lustik MB
Clin Ther; 2005 Jul; 27(7):1064-73. PubMed ID: 16154485
[TBL] [Abstract][Full Text] [Related]
4. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel.
Chodick G; Shalev V; Gerber Y; Heymann AD; Silber H; Simah V; Kokia E
Clin Ther; 2008 Nov; 30(11):2167-79. PubMed ID: 19108805
[TBL] [Abstract][Full Text] [Related]
5. New views on treatment of aromatase inhibitors induced arthralgia.
Xepapadakis G; Ntasiou P; Koronarchis D; Koufoudakis D; Panousis D; Grosomanidis D; Venizelos V; Georgiadis S
Breast; 2010 Jun; 19(3):249-50. PubMed ID: 20418100
[TBL] [Abstract][Full Text] [Related]
6. Aromatase inhibitor-associated arthralgia syndrome.
Burstein HJ
Breast; 2007 Jun; 16(3):223-34. PubMed ID: 17368903
[TBL] [Abstract][Full Text] [Related]
7. "I feel like I am 100 years old!" managing arthralgias from aromatase inhibitors.
Winters L; Habin K; Flanagan J; Cashavelly BJ
Clin J Oncol Nurs; 2010 Jun; 14(3):379-82. PubMed ID: 20529801
[TBL] [Abstract][Full Text] [Related]
8. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization.
Cooke CE; Lee HY; Tong YP; Haines ST
Curr Med Res Opin; 2010 Jan; 26(1):231-8. PubMed ID: 19921965
[TBL] [Abstract][Full Text] [Related]
9. Retrospective analysis of concurrent vs. sequential administration of radiotherapy and hormone therapy using aromatase inhibitor for hormone receptor-positive postmenopausal breast cancer.
Ishitobi M; Komoike Y; Motomura K; Koyama H; Nishiyama K; Inaji H
Anticancer Res; 2009 Nov; 29(11):4791-4. PubMed ID: 20032437
[TBL] [Abstract][Full Text] [Related]
10. Classification of and risk factors for estrogen deprivation pain syndromes related to aromatase inhibitor treatments in women with breast cancer: a prospective multicenter cohort study.
Laroche F; Coste J; Medkour T; Cottu PH; Pierga JY; Lotz JP; Beerblock K; Tournigand C; Declèves X; de Cremoux P; Bouhassira D; Perrot S
J Pain; 2014 Mar; 15(3):293-303. PubMed ID: 24365325
[TBL] [Abstract][Full Text] [Related]
11. Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study.
Garcia-Giralt N; Rodríguez-Sanz M; Prieto-Alhambra D; Servitja S; Torres-Del Pliego E; Balcells S; Albanell J; Grinberg D; Diez-Perez A; Tusquets I; Nogués X
Breast Cancer Res Treat; 2013 Jul; 140(2):385-95. PubMed ID: 23868189
[TBL] [Abstract][Full Text] [Related]
12. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905
[TBL] [Abstract][Full Text] [Related]
13. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
Winer EP; Hudis C; Burstein HJ; Wolff AC; Pritchard KI; Ingle JN; Chlebowski RT; Gelber R; Edge SB; Gralow J; Cobleigh MA; Mamounas EP; Goldstein LJ; Whelan TJ; Powles TJ; Bryant J; Perkins C; Perotti J; Braun S; Langer AS; Browman GP; Somerfield MR
J Clin Oncol; 2005 Jan; 23(3):619-29. PubMed ID: 15545664
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II placebo-controlled study to evaluate the efficacy of topical pure emu oil for joint pain related to adjuvant aromatase inhibitor use in postmenopausal women with early breast cancer: JUST (Joints Under Study).
Chan A; De Boer R; Gan A; Willsher P; Martin R; Zissiadis Y; Miller K; Bauwens A; Hastrich D
Support Care Cancer; 2017 Dec; 25(12):3785-3791. PubMed ID: 28691132
[TBL] [Abstract][Full Text] [Related]
15. Improved persistence and adherence to diuretic fixed-dose combination therapy compared to diuretic monotherapy.
Patel BV; Remigio-Baker RA; Thiebaud P; Preblick R; Plauschinat C
BMC Fam Pract; 2008 Nov; 9():61. PubMed ID: 18990240
[TBL] [Abstract][Full Text] [Related]
16. Adverse events and bone health during anastrozole therapy in postmenopausal Japanese breast cancer patients.
Sagara Y; Kosha S; Baba S; Dokiya F; Tamada S; Sagara Y; Matsuyama Y; Ohi Y; Ando M; Rai Y; Sagara Y; Douchi T
Breast Cancer; 2010 Jul; 17(3):212-7. PubMed ID: 19526308
[TBL] [Abstract][Full Text] [Related]
17. Rheumatic complaints in women taking aromatase inhibitors for treatment of hormone-dependent breast cancer.
Scarpa R; Atteno M; Peluso R; Costa L; Padula S; Di Minno D; Caso F; Iervolino S; Vitiello M; Del Puente A
J Clin Rheumatol; 2011 Jun; 17(4):169-72. PubMed ID: 21617557
[TBL] [Abstract][Full Text] [Related]
18. Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer.
Dent SF; Gaspo R; Kissner M; Pritchard KI
Breast Cancer Res Treat; 2011 Apr; 126(2):295-310. PubMed ID: 21249443
[TBL] [Abstract][Full Text] [Related]
19. Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-related arthralgia.
Dizdar O; Ozçakar L; Malas FU; Harputluoglu H; Bulut N; Aksoy S; Ozisik Y; Altundag K
J Clin Oncol; 2009 Oct; 27(30):4955-60. PubMed ID: 19752344
[TBL] [Abstract][Full Text] [Related]
20. Medication adherence and health care costs with the introduction of latanoprost therapy for glaucoma in a Medicare managed care population.
Bhosle MJ; Reardon G; Camacho FT; Anderson RT; Balkrishnan R
Am J Geriatr Pharmacother; 2007 Jun; 5(2):100-11. PubMed ID: 17719512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]